Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology

Clarksville, MD, November 10th, 2017 – Neuronascent, Inc. (www.neuronascent.com), a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today announced the European Patent Office has issued EU Patent No. 1937252, on October 25th, 2017, with claims of compounds and compositions for stimulating neurogenesis and inhibiting neuronal degeneration. Neuronascent’s novel compounds aim to treat numerous neurological conditions in humans, including Alzheimer’s disease, Parkinson’s disease, and psychiatric disorders. The claims cover small molecule candidates and the family around these candidates and their human use, adding to the patent coverage in the US and elsewhere. This patent is exclusively owned by Neuronascent.

“Our extensive intellectual property portfolio covers our lead small-molecule therapies aimed at improving and even reversing cognitive and motor deficits in neurological diseases with vast unmet need,” said Judith Kelleher-Andersson, Ph.D., Founder and Chief Executive Officer of Neuronascent. "Neuronascent's invention covers oral therapies designed to be disease-modifying, through a first-in-class neuron regenerative capacity that replaces lost neurons" Kelleher-Andersson stated. "This mechanism of action is distinct from neuroprotective agents alone that are currently being tested as treatments for chronic neurodegenerative disorders.”

About Neuronascent
Neuronascent, Inc., is a pre-IND stage biopharmaceutical company that discovers and develops orally-available, novel therapeutics aimed at halting or reversing chronic neurological disorders affecting tens of millions of people worldwide, including Alzheimer’s disease, Parkinson’s disease, psychiatric disorders and Down syndrome. Following the use of a unique discovery platform to identify novel agents that promote new neurons and ensure their survival and maturation, the Company completed the efficacy and safety studies required prior to human testing.

Contact: Judith Kelleher-Andersson, Ph.D. at investrelate@neuronascent.com

Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations.